Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

donation to psychedelics

Breaking News

21 Jun 2023

Breaking News: Toms Shoes Founder Pledges $100 million for Psychedelic Research

Blake Mycoskie, founder of Toms Shoes, has pledged to give $100 million to support psychedelic research and access...

By Microdose NewsDesk

Science

21 Jun 2023

New Study Shows Psychedelics Associated With Decrease Use of Other Substances

A new study shows that psychedelic use was associated with a decreased use of other drugs and substances....

By Microdose NewsDesk

Breaking News

20 Jun 2023

PharmaTher and Vitruvias Enter Into Commercialization Agreement for KETARX™ in the US

Pharmather has announced a collaboration agreement with Vitruvias Therapeutics for the commercialization of its KETARX (racemic ketamine) products in the U.S....

By Microdose NewsDesk

Science

16 Jun 2023

New Study: Psychedelics Reopen Social Reward Learning Period

A new study shows psychedelics reopen the brain for social reward learning, results that could have interesting implications for psychedelic medicine research...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

14 Jun 2023

Rhode Island House Passes Bill To Decriminalize Psilocybin

Rhode Island is moving closer to psychedelics medicine reform as the House of Representatives passed a bill this week to decriminalize possession and cultivation of psilocybin mushrooms....

By Microdose NewsDesk

Industry

7 Jun 2023

Psychedelics in Dubai: Therapeutic Role of Psychedelics Explored at Conference in the Arab Region

This academic event, set to take place on June 10th in Dubai, UAE, marks the first-ever conference in the region with dedicated programming exploring the field of psychedelic-assisted therapies....

By Microdose NewsDesk

Finance

6 Jun 2023

Compass Pathways’ Stock Soars as COMP360 Receives Patent Victory

Compass Pathways’ COMP360 has just received additional support for its IP strategy, with the US Patent and Trademark Office upholding patent protections on the compound....

By Microdose NewsDesk

Don’t Miss

5 Jun 2023

News You Might Have Missed: June 5th 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Industry

2 Jun 2023

Terran Biosciences Announces Licensing Deal with Pierre Fabre for Idazoxan; Completes Development Milestones

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.